MEI Pharma downgraded by Wells Fargo with a new price target
$MEIP
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo downgraded MEI Pharma from Overweight to Equal Weight and set a new price target of $2.00 from $13.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/23/2024 | Buy → Hold | Laidlaw | |
| 3/25/2022 | $4.00 → $1.00 | Buy → Hold | Jefferies |
| 3/25/2022 | $13.00 → $2.00 | Overweight → Equal Weight | Wells Fargo |
| 3/25/2022 | $6.00 → $2.00 | Buy → Hold | Stifel |
| 2/3/2022 | $4.00 | Buy | Jefferies |
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company's succession planning, Brian Drazba's tenure as Chief Financial Officer of the Company will end no later than September 1, 2023, and the Company has hired Justin (Jay) File as his successor. Mr. File joined the Company on June 12, 2023 as Executive Vice President, Finance and will be appointed Chief Financial Officer upon Mr. Drazba's departure. "Brian has been a true asset to MEI providing invaluable fiscal and business leadership as we advanced our clinical programs and executed various transactions, incl
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company's previously announced succession plan, Daniel P. Gold, Ph.D's tenure as the president and chief executive officer of MEI will end on June 2, 2023 and the Company's board of directors has appointed David M. Urso as his successor. Mr. Urso, who joined the Company in 2014 and has been serving as the company's chief operating officer since 2018, will also join the board of directors. Dr. Gold will remain on MEI's board, where he will continue to share his extensive knowledge and experience with the company.
MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Frese will be responsible for the strategy and processes related to building and retaining an exceptional team of professionals. Ms. Frese's appointment is effective immediately. Ms. Frese joins MEI with over 30 years of human resource experience across a variety of industries, including biotech, consulting, hospitality, and engineering. Most recently, she served as chief human resources officer at Vyripharm En
SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)
SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)
SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)
Laidlaw downgraded MEI Pharma from Buy to Hold
Jefferies downgraded MEI Pharma from Buy to Hold and set a new price target of $1.00 from $4.00 previously
Wells Fargo downgraded MEI Pharma from Overweight to Equal Weight and set a new price target of $2.00 from $13.00 previously
4 - MEI Pharma, Inc. (0001262104) (Issuer)
4 - MEI Pharma, Inc. (0001262104) (Issuer)
4 - MEI Pharma, Inc. (0001262104) (Issuer)
Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme
Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritization of Voruciclib Program Development-- -- MEI Begins Fourth Fiscal Quarter with $56.6 Million in Cash -- MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.
4 - MEI Pharma, Inc. (0001262104) (Issuer)
4 - MEI Pharma, Inc. (0001262104) (Issuer)
4/A - MEI Pharma, Inc. (0001262104) (Issuer)
8-K - MEI Pharma, Inc. (0001262104) (Filer)
10-Q - MEI Pharma, Inc. (0001262104) (Filer)
8-K - MEI Pharma, Inc. (0001262104) (Filer)
Laidlaw & Co. analyst Yale Jen downgrades MEI Pharma (NASDAQ:MEIP) from Buy to Hold.
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa
Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme
Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company's exclusive financial advisor to assist in its previously announced process to review and evaluate strategic alternatives. The Company remains focused on maximizing the value of its assets for its stockholders. There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been c